Author

Josu Santamaria

Institutions: Bristol-Myers Squibb (Switzerland), Incyte (United States)

Observed institutions: Bristol-Myers Squibb (Switzerland), Incyte (United States)

OpenAlex ID: A5111241891

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study

2025 · Manali Kamdar, Scott R. Solomon, et al. · Journal of Clinical Oncology · 46

Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.

2024 · Manali Kirtikumar Kamdar, Scott R. Solomon, et al. · Journal of Clinical Oncology · 18

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

2025 · Jason Gotlib, John Mascarenhas, et al. · Blood · 2

Works count: 3

Citation count: 65

H-index: 2

I10-index: 2